Healio22h
Positive results showcase icotrokinra’s ‘unique’ mechanism of action in plaque psoriasis
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
Applied Clinical Trials Online18h
Johnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
AFP20h
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to JNJ Innovative ...